Achilles Therapeutics is making significant strides in its Phase 1/2a clinical trials, focusing on neoantigen reactive T-cell therapy for non-small cell lung cancer (NSCLC) and melanoma. The company’s recent updates highlight the dosing of the first three patients utilizing enhanced host conditioning (EHC) in both the CHIRON and THETIS trials, which are assessing the efficacy of ATL001, a clonal neoantigen reactive T-cell (cNeT) therapy.
Patient Dosing and Initial Observations
The initial administration of ATL001 marks a pivotal moment for Achilles Therapeutics. The incorporation of EHC appears to enhance the persistence and engraftment of cNeT therapies in these patients. The company has successfully manufactured and delivered over 100 million cNeT products and five products exceeding one billion cNeT. With a promising outlook, Achilles plans to release results from the CHIRON and THETIS trials, including crucial insights on clinical activity and translational science, by the end of this year.
Collaboration with Arcturus Therapeutics
In addition to its trial updates, Achilles Therapeutics has announced a collaboration with Arcturus Therapeutics. This partnership aims to leverage Achilles’s artificial intelligence-driven tumor targeting technology alongside Arcturus’s self-amplifying mRNA platform. The goal is to explore the potential of second-generation mRNA cancer vaccines that may enhance patient outcomes in the future.
Insights from Ongoing Trials
Iraj Ali, PhD, CEO of Achilles Therapeutics, expressed enthusiasm about the interim data shared during the second quarter. The CHIRON and THETIS trials focus on tumor-infiltrating lymphocytes (TILs) and their clinical applications. The integration of EHC has led to the addition of a new cohort in these studies to assess cNeT persistence and clinical effectiveness. This innovation showcases the versatility of Achilles’s platform, particularly the PELEUS technology, which identifies tumor targets that the immune system can recognize effectively across various therapeutic modalities.
Early Efficacy Data
Achilles Therapeutics previously presented early efficacy data from its trials at the ESMO Immuno-Oncology Congress. Among patients with NSCLC in the CHIRON trial, investigators noted a 71% overall durable clinical benefit rate at 12 weeks, with one partial response and six instances of stable disease. Similarly, half of the melanoma patients exhibited stable disease, further underlining the potential effectiveness of cNeT therapies.
Mechanistic Insights and Monitoring
Sergio Quezada, PhD, the Chief Scientific Officer at Achilles, emphasized the unique mechanistic insights derived from the translational science platform. This platform allows for an in-depth assessment of phenotypic markers and the functional capacity of cNeT components. By tracking specific cNeT targets in patient blood samples, the team can monitor dosage, functional markers, and other critical features related to patient outcomes.
Competitive Landscape
Achilles Therapeutics is not alone in the race to develop innovative cell therapies for NSCLC. Recently, Kiromic BioPharma announced receiving FDA fast-track designation for its investigational allogeneic gamma delta T-cell therapy, KB-GDT-01, currently being evaluated in a Phase 1/2 trial. This highlights the increasing interest and investment in cell-based therapies targeting NSCLC.
Future Prospects
As Achilles Therapeutics continues its trials and collaborations, the landscape of cancer treatment is poised for significant advancements. The integration of personalized therapy approaches, such as cNeT therapies and mRNA vaccines, may redefine standards in oncology. The upcoming results from the CHIRON and THETIS trials will be critical in assessing the impact of these therapies on patient outcomes.
Key Takeaways
- Achilles Therapeutics has begun dosing patients with enhanced host conditioning in its CHIRON and THETIS trials for NSCLC and melanoma.
- The collaboration with Arcturus Therapeutics aims to explore second-generation mRNA cancer vaccines.
-
Early efficacy data reveals promising results, including a 71% durable clinical benefit rate in NSCLC patients.
-
The unique translational science platform provides mechanistic insights that enhance monitoring and understanding of cNeT therapies.
-
The competitive landscape for NSCLC therapies is growing, with other companies like Kiromic BioPharma also advancing novel treatments.
In conclusion, Achilles Therapeutics is at the forefront of developing innovative therapies for cancer treatment, showing promise in both trial results and strategic collaborations. The ongoing research and results could significantly impact the future of cancer care, making it an exciting time for the field.
Source: www.cgtlive.com